NeuroMetrix and Eli Lilly Partner to Improve Awareness and Detection of Diabetic Peripheral Neuropathy

The partnership aims to increase awareness and understanding of diabetic peripheral neuropathy (DPN) diagnosis among physicians who manage patients with diabetes. DPN is a common chronic complication of diabetes, causing microvascular damage to nerves, which can lead to foot ulcers and amputations. The condition affects 60 to 70% of people with diabetes, resulting in over 80,000 amputations annually in the United States. Early detection of DPN is crucial for preventing advanced damage, and a new partnership between NeuroMetrix and Eli Lilly seeks to educate physicians on the importance of prompt diagnosis.

Key Takeaways:

• The partnership between NeuroMetrix and Eli Lilly aims to increase awareness and detection of diabetic peripheral neuropathy (DPN) among endocrinologists and internal medicine physicians.
• DPN is a common chronic complication of diabetes, causing microvascular damage to nerves, which can lead to foot ulcers and amputations.
• 60 to 70% of people with diabetes have some form of nerve damage, and over 80,000 amputations are performed each year due to DPN.
• Early detection of DPN is crucial for preventing advanced damage.
• NeuroMetrix's NC-stat System allows for the objective quantification of neuropathies, significantly enhancing the physician's ability to diagnose and manage neuropathies.
• The partnership will conduct a series of 84 educational and development programs across the country over the next 18 months, focusing on diabetic microvascular complications and the diagnosis of DPN.

Statistics:

• 60 to 70% of people with diabetes have some form of nerve damage.
• Over 80,000 amputations are performed each year due to DPN.
• The NC-stat System is used in over 2,200 physician practices and clinics throughout the United States.

Sources:

• Health & Medicine Week (2005) Copyright 2005, Health & Medicine Week via NewsRx.com.